Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

https://doi.org/10.1056/NEJMoa2517384

Acute versus Long-term anti-GPVI Treatment: From Receptor Blockade to Partial Downregulation

Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study

Expert Insights on Achieving Normalization for Hemophilia A Patients

This article features Cedric Hermans, MD, PhD, FRCP, a professor and head of hematology at Saint-Luc University Hospital in Brussels, discus

GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer

CME Event: From Treatment Advances to Individualized Care in Hemophilia - August 2026

A CME/CNE/CPE/IPCE educational event titled "From Treatment Advances to Individualized Care in Hemophilia" scheduled for August 14, 2026, at